Organon & Co. (NYSE:OGN) Issues Earnings Results, Misses Estimates By $0.09 EPS

Organon & Co. (NYSE:OGN) announced its quarterly earnings data on Thursday. The company reported $0.83 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09), Zacks reports. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. Organon & Co. updated its FY 2025 guidance to EPS.

Organon & Co. Stock Up 8.6 %

OGN stock traded up $1.27 during trading hours on Thursday, hitting $15.97. The company’s stock had a trading volume of 6,160,096 shares, compared to its average volume of 2,694,525. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The company has a market capitalization of $4.11 billion, a PE ratio of 3.17, a price-to-earnings-growth ratio of 0.83 and a beta of 0.76. Organon & Co. has a 12 month low of $13.87 and a 12 month high of $23.10. The stock has a 50 day moving average price of $15.33 and a two-hundred day moving average price of $17.54.

Wall Street Analyst Weigh In

Separately, TD Cowen raised shares of Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Organon & Co. presently has an average rating of “Hold” and a consensus target price of $21.33.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.